- Home
- /
- PT-141 (Bremelanotide) 10mg
PT-141 (Bremelanotide) 10mg
Certificate of Analysis
HPLC + Mass Spectrometry included with order
PT-141, also known as Bremelanotide, is a synthetic cyclic heptapeptide and melanocortin receptor agonist. It primarily targets the MC3R and MC4R receptors in the central nervous system, which are involved in the regulation of sexual arousal, energy homeostasis, and inflammatory responses.
PT-141 is notable for being the first compound in its class to receive FDA approval (as Vyleesi) for a specific indication related to sexual function. Unlike PDE5 inhibitors which act on vascular mechanisms, PT-141 operates through central nervous system pathways, representing a fundamentally different mechanism of action.
Research continues to investigate PT-141 across melanocortin receptor signalling, inflammatory modulation, and neurological pathways. It has the highest verified purity of any product in the Kyrolab catalogue.
Independently Verified Purity: 99.942% — HIGHEST IN CATALOGUE
Tested by Janoshik Analytical (Prague) — Task #76306, 28 August 2025.
3 separate vials tested for batch consistency:
Vial 1: 12.87mg, 99.939% purity
Vial 2: 12.77mg, 99.937% purity
Vial 3: 12.96mg, 99.949% purity
Average overfill: 29% above stated 10mg dose.
Verification: janoshik.com/verify — Key:
I46YV8KG4GAB
Specifications
| Also Known As | Bremelanotide, Vyleesi (FDA-approved name) |
| Molecular Weight | 1025.18 g/mol |
| CAS | 189691-06-3 |
| Sequence | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH |
| Receptor Targets | MC3R, MC4R |
| Appearance | White lyophilised powder |
| Storage | 2-8°C, protect from light |
This product is sold strictly for in-vitro research and laboratory purposes. Not for human or animal consumption. Not evaluated by the MHRA or FDA. Must be 18+ to purchase. By purchasing, you agree to our Research Disclaimer and Terms of Service.
| Catalogue Number | KYR-PT14110MG |
| Compound Name | PT-141 (Bremelanotide) 10mg |